AR046758A1 - Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c - Google Patents
Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis cInfo
- Publication number
- AR046758A1 AR046758A1 ARP040104589A ARP040104589A AR046758A1 AR 046758 A1 AR046758 A1 AR 046758A1 AR P040104589 A ARP040104589 A AR P040104589A AR P040104589 A ARP040104589 A AR P040104589A AR 046758 A1 AR046758 A1 AR 046758A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- heterocyclyl
- heteroaryl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Abstract
El presente revela compuestos que tienen actividad inhibidora de la proteasa del VHC como así también métodos para preparar tales compuestos. En otra realización, el presente revela composiciones farmacéuticas que comprenden tales compuestos como así también métodos para utilizarlos para tratar trastornos asociados con la proteasa del VHC. Reivindicación 1: Un compuesto, o enantiómeros, estereoisómeros, rotámeros, tautómeros, diastereómeros o racematos de dicho compuesto, o una sal, solvato o éster aceptable para uso farmacéutico de dicho compuesto, teniendo dicho compuesto la estructura general que se muestra en la fórmula (1), en la cual: R1 es H, OR8, NR9R10 o CHR9R10, donde R8, R9 y R10 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo integrado por H, alquilo-, arilo-, heteroalquilo-, heteroarilo-, cicloalquilo-, cicloalquilo-, arilalquilo-, y heteroarilalquilo; E y J pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo integrado por R, OR, NHR, NRR7, SR, halo y S(O2)R, o E y J pueden conectarse directamente entre sí para formar ya sea un cicloalquilo de tres a ocho miembros, o un resto heterociclilo de tres a ocho miembros; Z es N(H), N(R) u O, con la salvedad de que cuando Z sea O, G esté presente o ausente y si G está presente cuando Z es O entonces G es C(=O); G puede estar presente o ausente, y si G está presente, G es C(=O) o S(O2), y cuando G está ausente, Z está directamente conectado a Y; Y se selecciona del grupo de fórmulas (2); R, R7 R2, R3, R4 y R5 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo integrado por H, alquilo-, alquenilo-, alquinilo-, cicloalquilo-, heteroalquilo-, heterociclilo-, arilo-, heteroarilo-, (cicloalquil)alquilo-, (heterociclil)alquilo-, aril-alquilo- y heteroaril-alquilo-, donde cada uno de dichos heteroalquilo, heteroarilo y heterociclilo en forma independiente tiene de uno a seis átomos de oxígeno, nitrógeno, azufre, o fósforo; donde cada uno de dichos restos alquilo, heteroalquilo, alquenilo, alquinilo, arilo, heteroarilo, cicloalquilo y heterociclilo pueden estar no sustituidos u opcionalmente sustituidos en forma independiente con uno o más restos seleccionados del grupo integrado por alquilo, alquenilo, alquinilo, arilo, aralquilo, cicloalquilo, heterociclilo, halo, hidroxi, tio, alcoxi, ariloxi, alquiltio, ariltio, amino, amido, éster, ácido, carboxílico, carbamato, urea, cetona, aldehído, ciano, nitro, sulfonamido, sulfóxido, sulfona, sulfonil urea, hidracida e hidroxamato.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52884503P | 2003-12-11 | 2003-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046758A1 true AR046758A1 (es) | 2005-12-21 |
Family
ID=34699904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104589A AR046758A1 (es) | 2003-12-11 | 2004-12-09 | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c |
Country Status (18)
Country | Link |
---|---|
US (1) | US7485625B2 (es) |
EP (1) | EP1742913A1 (es) |
JP (1) | JP2007513971A (es) |
KR (1) | KR20060118532A (es) |
CN (1) | CN100509784C (es) |
AR (1) | AR046758A1 (es) |
AU (1) | AU2004298498B2 (es) |
BR (1) | BRPI0416902A (es) |
CA (1) | CA2549167A1 (es) |
CO (1) | CO5700736A2 (es) |
EC (1) | ECSP066626A (es) |
IL (1) | IL176237A0 (es) |
NO (1) | NO20063205L (es) |
PE (1) | PE20050940A1 (es) |
RU (1) | RU2006124594A (es) |
TW (1) | TW200518746A (es) |
WO (1) | WO2005058821A1 (es) |
ZA (1) | ZA200604638B (es) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9712544B1 (pt) | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
AU2006252553B2 (en) * | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
EP2614709A1 (en) * | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
BRPI0617274A2 (pt) * | 2005-10-11 | 2011-07-19 | Intermune Inc | compostos e métodos para a inibição de replicação viral de hepatite c |
US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1951748B1 (en) | 2005-11-11 | 2013-07-24 | Vertex Pharmaceuticals, Inc. | Hepatitis c virus variants |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
WO2007083620A1 (ja) | 2006-01-20 | 2007-07-26 | Kaneka Corporation | β-アミノ-α-ヒドロキシ酸アミド誘導体の製造法 |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CN101466727B (zh) | 2006-04-11 | 2012-10-17 | 诺瓦提斯公司 | Hcv/hiv抑制剂及其用途 |
WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
RU2419626C2 (ru) | 2006-05-23 | 2011-05-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
JP5301270B2 (ja) * | 2006-05-26 | 2013-09-25 | 株式会社カネカ | 光学活性3−アミノ−2−ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法 |
US9526769B2 (en) * | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
UY30437A1 (es) * | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
DE102006059317A1 (de) * | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden |
RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
US7662779B2 (en) * | 2006-08-11 | 2010-02-16 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis C serine protease inhibitors |
AU2007284027A1 (en) | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2008027397A2 (en) * | 2006-08-28 | 2008-03-06 | Vertex Pharmaceuticals Incorporated | Method for identifying protease inhibitors |
US20100216161A1 (en) | 2009-02-26 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Method for identifying protease inhibitors |
DE102006042147A1 (de) * | 2006-09-06 | 2008-03-27 | Dynamit Nobel Gmbh Explosivstoff- Und Systemtechnik | Hydrochloride von 3-Amino-2-hydroxycarbonsäureamiden |
US8003604B2 (en) * | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
EP2117537A1 (en) | 2007-02-09 | 2009-11-18 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
EP2185524A1 (en) * | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
KR101396696B1 (ko) * | 2007-10-10 | 2014-05-16 | 노파르티스 아게 | 스피로피롤리딘, 및 hcv 및 hiv 감염에 대한 그의 용도 |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
US8268777B2 (en) * | 2007-12-05 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Oximyl macrocyclic derivatives |
CN101903351B (zh) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
JP2011051896A (ja) * | 2007-12-21 | 2011-03-17 | Kaneka Corp | N−シクロプロピル−3−アミノ−2−ヒドロキシヘキサン酸アミド塩酸塩の製造方法 |
BRPI0911260A2 (pt) | 2008-04-15 | 2015-09-29 | Intermune Inc | composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos |
US20090285773A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN101580535B (zh) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
WO2009148923A1 (en) * | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US20100272674A1 (en) * | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
EP2385838A1 (en) | 2009-01-07 | 2011-11-16 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
LT2477980T (lt) * | 2009-09-15 | 2016-09-26 | Taigen Biotechnology Co., Ltd. | Hcv proteazės slopikliai |
US20120276047A1 (en) | 2009-11-25 | 2012-11-01 | Rosenblum Stuart B | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
BR112012021556A2 (pt) * | 2010-02-25 | 2017-03-21 | Ver Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patiëntenzorg | processo para a preparação de peptídeos prolila substituídos e peptidomiméticos similares |
PE20130062A1 (es) | 2010-03-09 | 2013-02-28 | Merck Sharp & Dohme | Compuestos de sililo triciclicos fusionados para el tratamiento de enfermedades virales |
CA2805440A1 (en) | 2010-07-26 | 2012-02-09 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
WO2012050848A1 (en) | 2010-09-29 | 2012-04-19 | Schering Corporation | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
JP2014515023A (ja) | 2011-04-13 | 2014-06-26 | メルク・シャープ・アンド・ドーム・コーポレーション | 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法 |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
WO2013178682A2 (en) | 2012-05-30 | 2013-12-05 | Chemo Ibérica, S.A. | Multicomponent process for the preparation of bicyclic compounds |
IN2014MN02533A (es) | 2012-06-13 | 2015-07-24 | Janssen Pharmaceutica Nv | |
CN102875649B (zh) * | 2012-09-26 | 2014-04-16 | 深圳翰宇药业股份有限公司 | 一种制备特拉匹韦及其中间体的方法及所述中间体 |
CN102875648B (zh) * | 2012-09-26 | 2014-02-19 | 深圳翰宇药业股份有限公司 | 一种制备特拉匹韦的方法 |
US10167298B2 (en) | 2013-10-30 | 2019-01-01 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof |
CN104610272B (zh) * | 2013-11-05 | 2017-03-29 | 上海唐润医药科技有限公司 | 环状黄酮或异黄酮类化合物及其用途 |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
CA2994496A1 (en) * | 2017-02-14 | 2018-08-14 | Abbvie Inc. | Methods for treating hcv |
US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3216325A (en) * | 1962-04-16 | 1965-11-09 | Dole Valve Co | Pneumatic control system |
IL152022A0 (en) | 2000-04-03 | 2003-04-10 | Vertex Pharma | Compounds useful as protease inhibitors and pharmaceutical compositions containing the same |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AU2001276988B2 (en) * | 2000-07-21 | 2007-01-25 | Dendreon Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
WO2002048172A2 (en) * | 2000-12-12 | 2002-06-20 | Schering Corporation | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
MXPA04007163A (es) | 2002-01-23 | 2004-10-29 | Schering Corp | Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c. |
-
2004
- 2004-12-09 TW TW093138050A patent/TW200518746A/zh unknown
- 2004-12-09 CN CNB2004800367937A patent/CN100509784C/zh not_active Expired - Fee Related
- 2004-12-09 US US11/007,910 patent/US7485625B2/en not_active Expired - Fee Related
- 2004-12-09 BR BRPI0416902-6A patent/BRPI0416902A/pt not_active IP Right Cessation
- 2004-12-09 AU AU2004298498A patent/AU2004298498B2/en not_active Expired - Fee Related
- 2004-12-09 RU RU2006124594/04A patent/RU2006124594A/ru not_active Application Discontinuation
- 2004-12-09 PE PE2004001217A patent/PE20050940A1/es not_active Application Discontinuation
- 2004-12-09 AR ARP040104589A patent/AR046758A1/es unknown
- 2004-12-09 CA CA002549167A patent/CA2549167A1/en not_active Abandoned
- 2004-12-09 KR KR1020067011224A patent/KR20060118532A/ko not_active Application Discontinuation
- 2004-12-09 JP JP2006544061A patent/JP2007513971A/ja not_active Ceased
- 2004-12-09 WO PCT/US2004/041579 patent/WO2005058821A1/en active Application Filing
- 2004-12-09 EP EP04813838A patent/EP1742913A1/en not_active Withdrawn
-
2006
- 2006-06-06 ZA ZA200604638A patent/ZA200604638B/en unknown
- 2006-06-08 EC EC2006006626A patent/ECSP066626A/es unknown
- 2006-06-09 CO CO06056306A patent/CO5700736A2/es not_active Application Discontinuation
- 2006-06-11 IL IL176237A patent/IL176237A0/en unknown
- 2006-07-10 NO NO20063205A patent/NO20063205L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20060118532A (ko) | 2006-11-23 |
AU2004298498B2 (en) | 2008-09-11 |
US7485625B2 (en) | 2009-02-03 |
EP1742913A1 (en) | 2007-01-17 |
CN1890215A (zh) | 2007-01-03 |
RU2006124594A (ru) | 2008-01-27 |
NO20063205L (no) | 2006-09-08 |
ZA200604638B (en) | 2007-04-25 |
CN100509784C (zh) | 2009-07-08 |
TW200518746A (en) | 2005-06-16 |
JP2007513971A (ja) | 2007-05-31 |
BRPI0416902A (pt) | 2007-01-16 |
CA2549167A1 (en) | 2005-06-30 |
US20050153900A1 (en) | 2005-07-14 |
PE20050940A1 (es) | 2005-11-08 |
IL176237A0 (en) | 2006-10-05 |
AU2004298498A1 (en) | 2005-06-30 |
WO2005058821A1 (en) | 2005-06-30 |
ECSP066626A (es) | 2006-10-25 |
CO5700736A2 (es) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046758A1 (es) | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
AR048413A1 (es) | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
AR047902A1 (es) | Compuestos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
AR047903A1 (es) | Compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
AR048023A1 (es) | Cetoamidas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
AR047901A1 (es) | Inhibidores de proteasa ns3 del virus de la hepatitis c | |
AR048241A1 (es) | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c . | |
EA201101492A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
AR038214A1 (es) | Compuestos de prolina como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
AR038183A1 (es) | Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c | |
AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
AR054197A1 (es) | Medicamentos y metodos combinando un inhibidor de la proteasa hcv y un competidor akr | |
BRPI0509258A8 (pt) | composto de 8-oxoadenina 9-substituída | |
AR034127A1 (es) | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento | |
ECSP066456A (es) | Inhibidores macrocíclicos de la serina proteasa ns3 del virus de la hepatitis c | |
ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
NO20062267L (no) | Hepatitt C virus inhibitorer | |
NO20062185L (no) | Hepatitt C virus-inhibitorer | |
AR047339A1 (es) | Derivados de difenilazetidona.proceso de obtencion. | |
AR030558A1 (es) | COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA, | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
AR061008A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
EA200800476A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
NO20062339L (no) | Hepatitt C virus-inhibitoerer | |
EA200702493A1 (ru) | Соединения и способы лечения или предотвращения флавивирусных инфекций |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |